Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Vaxart, Inc (VXRT) operate in?
Vaxart, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vaxart, Inc (VXRT) current stock price?
As of the latest data, Vaxart, Inc stock price is $0.57, with a previous close of $0.57. Vaxart, Inc lost -$0.00 in the last trading session, representing a -0.11% loss.
What is Vaxart, Inc (VXRT) current market capitalization?
Vaxart, Inc market cap is approximately 137.80 million.
What is Vaxart, Inc (VXRT) Earnings Per Share (EPS)?
The trailing EPS is $0.16, and the forward EPS is -$1.03.
What is Vaxart, Inc (VXRT) Price-to-Earnings (P/E) ratio?
Vaxart, Inc current P/E ratio is 3.56.
What is Vaxart, Inc (VXRT) EBITDA?
Vaxart, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 6.84 million.
Does Vaxart, Inc (VXRT) pay dividends?
No. Vaxart, Inc does not pay a dividend.
How did Vaxart, Inc (VXRT) perform in its most recent earnings report?
In the last report (March 31, 2026), Vaxart, Inc posted an EPS surprise of 0% and a revenue surprise of -40.11%.
When is Vaxart, Inc (VXRT) next earnings report?
Vaxart, Inc is expected to release its next earnings report on June 30, 2026.
What is Vaxart, Inc (VXRT) beta (volatility) score?
Vaxart, Inc has a beta of 1.095, meaning its volatility is roughly in line with the market.
